A recent Haematology digest,
as sent to subscribers

Study Type: Expert consensus statement (international multidisciplinary panel), not original research

Key Question: How should T-LGL leukaemia be diagnosed, when should treatment be initiated, and how should response be assessed in a standardised way across clinical practice and trials?

Key Findings:

• Highlights current lack of uniform diagnostic and response criteria, causing heterogeneity across studies and hindering cross-trial comparison.
• Establishes evidence-based, consensus-derived criteria for diagnosis, treatment initiation thresholds, and response assessment, developed by the International LGLL Consortium.
• No new efficacy or outcome data presented; this is a framework-defining document.

Clinical Relevance: Provides UK haematologists with a much-needed standardised framework to diagnose and manage this rare, under-recognised leukaemia consistently, supporting trial enrolment and NHS specialist service alignment with international practice.

Limitations: As a consensus opinion rather than primary data, recommendations require prospective validation before widespread adoption as standard of care.

Study Type: Translational/mechanistic study (correlative analysis of clinical trial samples plus laboratory experiments)

Key Question: Does T-cell immunosenescence, rather than classical exhaustion, explain variable CD19 CAR T-cell efficacy in CLL?

Key Findings:

• Nonresponders/short partial responders showed higher senescence and SASP gene programs in preinfusion CTL019 products, correlating with poor CAR T-cell expansion and worse survival.
• Poor responders had CD27⁻CD28⁻/KLRG1⁺ CD8 T-cells at apheresis, lower CD27 expression, reduced TCR diversity, and a circulating SASP-like inflammatory milieu.
• Senescent features (SA-β-gal, p16, p53, DNA damage) limited proliferative capacity and cytotoxic reserve; ibrutinib reduced senescence/SASP markers and improved CAR T-cell expansion, including in an ibrutinib-resistant model.

Clinical Relevance: Identifies immunosenescence as a measurable, potentially modifiable determinant of CAR T-cell failure in CLL, supporting consideration of BTK-inhibitor priming or senescence biomarker screening to improve outcomes within UK CAR-T commissioning pathways.

Limitations: Findings are largely correlative and derived from a modest CTL019 patient cohort plus in vitro models, requiring prospective validation before influencing manufacturing or treatment protocols.

Study Type: Preclinical mechanistic study (murine and human HSC models)

Key Question: What drives haematopoietic stem cell (HSC) aging, and can this be therapeutically reversed?

Key Findings:

• Aged HSCs show elevated sphingosine-1-phosphate (S1P), which inhibits HDAC activity, increases H3K9 acetylation, and upregulates Lpcat2, driving accumulation of pro-ferroptotic phospholipids.
• Genetic or pharmacological Sphk2 inhibition lowers S1P, reduces Lpcat2 expression, and attenuates ferroptotic stress in both aged mouse and human HSCs.
• Sphk2 inhibition improved HSC function, restored immune homeostasis, and modestly extended lifespan in aged mice.

Clinical Relevance: Identifies sphingosine kinase 2/S1P signalling as a novel druggable pathway for HSC rejuvenation, with potential future relevance to ageing-related bone marrow failure, transplant conditioning, or immunosenescence management in UK haematology practice.

Limitations: Findings are based on animal and in vitro human cell models; clinical efficacy and safety of Sphk2 inhibition in humans remain unestablished.

Study Type: Preclinical translational research (in vitro and murine xenograft study)

Key Question: Can TCR-engineered T cells targeting immunoglobulin heavy chain constant domains provide effective, isotype-selective killing of multiple myeloma cells while sparing normal tissue?

Key Findings:

• Nine HLA-presented IgG/IgA-derived peptides were identified; high-avidity TCRs against four epitopes were isolated and showed selective recognition of IgG- or IgA-expressing MM lines, sparing antigen-negative cells.
• TCR-T cells lysed patient-derived MM cells ex vivo and eradicated established IgA/IgG-expressing MM tumours in xenograft models, with strict HLA restriction and no cross-reactivity against non-B-lineage cells or healthy tissue (aside from isotype-matched B-cell depletion).
• Dendritic cells could cross-present immunoglobulin peptides at high serum Ig concentrations, suggesting a mechanism for enhanced in vivo T-cell activation.

Clinical Relevance: This offers a novel, isotype-selective TCR-T approach for relapsed/refractory MM that may preserve humoral immunity better than pan-B-cell or BCMA-directed CAR-T strategies currently used in NHS practice.

Limitations: Findings are based on preclinical models only; clinical efficacy, safety, and durability in patients remain unestablished.

Study Type: Cohort study with translational/genetic analysis (human SNP association study plus murine knockout validation)

Key Question: What genetic factors, beyond VWF levels, ABO blood group and age, modify FVIII clearance in haemophilia A patients?

Key Findings:

• VWF, ABO group and age together explained <40% of variance in FVIII clearance in 52 haemophilia A patients across 106 SNPs at 43 loci.
• Known clearance receptor loci (STAB2, ASGR2, CLEC4M) were confirmed; four novel signals (TC2N, ADAMTS13, RASIP1/MAMSTR/FUT2, C2CD4B) were newly associated with FVIII PK.
• FUT2 Secretor status affected FVIII half-life (prolonged in non-secretors vs secretors); Fut2 knockout mice showed significantly elevated plasma FVIII, supporting causality.

Clinical Relevance: These findings could improve individualised FVIII dosing and PK-guided prophylaxis in UK haemophilia centres, and highlight FVIII/VWF pathway genetics as a potential modifiable cardiovascular risk factor.

Limitations: Small human cohort (n=52) limits statistical power and generalisability of genetic associations.

Study Type: Translational research (murine model plus single-cell analysis of clinical transplant samples)

Key Question: Does timing of calcineurin inhibitor (CNI) administration relative to post-transplant cyclophosphamide (PTCy) affect donor T-cell exhaustion and chronic GVHD (cGVHD) risk after haploidentical HCT?

Key Findings:

• Early tacrolimus (before PTCy) in PTCy-haplo-PBSCT patients promoted expansion of effector-like CD8+ intermediate-exhausted T cells (Tex-int) and CD4+ cytotoxic T cells, both retaining TCR/PD-1 blockade responsiveness.
• Expansion of these subsets by day 28 predicted subsequent cGVHD development.
• Delaying tacrolimus to day 5 post-PTCy significantly reduced expansion of these pathogenic effector-like T-cell populations, mirroring murine findings with delayed cyclosporine.

Clinical Relevance: These findings suggest that CNI timing relative to PTCy is a modifiable factor influencing cGVHD risk in haploidentical transplant protocols increasingly used in UK haematology practice, with Tex-int and CD4+ CTL populations potentially serving as biomarkers guiding preemptive cGVHD therapy.

Limitations: Findings derive from a single-centre translational study combining murine and limited clinical single-cell data, requiring validation in larger prospective cohorts before altering CNI timing in practice.

Study Type: Preclinical laboratory study (mechanistic + in vivo model, drug development)

Key Question: Does wild-type NUP214 sustain leukaemia stem cell (LSC) survival in AML via metabolic regulation, and can it be therapeutically targeted?

Key Findings:

• NUP214 suppresses ferroptosis in LSCs by nuclear repression of HMOX1 and ALOX15 (via blocking Sub1-mediated RNA Pol II recruitment), limiting heme catabolism, Fe²⁺ accumulation, and lipid peroxidation.
• NUP214 loss induces heme exhaustion, excess lipid peroxidation, and ferroptosis, impairing AML progression.
• Novel degrader compound 0449-b (recruits NUP214 to Cullin5-Rbx2 for neddylation/proteasomal degradation) triggers LSC ferroptosis and shows anti-leukaemic activity in vivo while sparing normal HSCs.

Clinical Relevance: Identifies NUP214 as a novel, LSC-selective therapeutic target with a first-in-class degrader strategy, offering a potential future ferroptosis-inducing approach for relapsed/refractory AML relevant to UK haematology drug development pipelines.

Limitations: Findings are based on preclinical models; clinical efficacy, pharmacokinetics, and safety of 0449-b in humans remain unestablished.

Study Type: Retrospective cohort/biomarker discovery study

Key Question: Can DNA methylation profiling improve prognostic risk stratification in AML beyond standard genetic and clinical markers?

Key Findings:

• Unsupervised methylation analysis identified 13 epitypes in 1,262 de novo AML patients; some patients lacking cardinal genetic lesions (e.g., CEBPAbZIP, FLT3-ITD, CBF, KMT2A-r) showed "alteration-like" methylation patterns with outcomes resembling patients harbouring the actual mutation.
• A novel STAT hypomethylation signature (SHS), enriched in FLT3-ITD patients, identified a subgroup with inferior outcomes, adding prognostic granularity beyond FLT3-ITD status alone.
• Machine learning models incorporating methylation signatures alongside genetic/clinical/demographic variables significantly improved prediction of remission, relapse, and overall survival.

Clinical Relevance: For UK haematology services increasingly using molecular profiling in AML risk stratification (per ELN/WHO frameworks), methylation-based signatures could refine treatment allocation, particularly identifying occult high-risk biology in patients lacking canonical mutations.

Limitations: Retrospective design without independent validation cohort or prospective outcome testing limits immediate clinical applicability.